Potential antiedematous effects of intravitreous anti-VEGF, unrelated to VEGF neutralization

Béhar-Cohen, Francine; Dernigoghossian, Marilyn; Andrieu-Soler, Charlotte; Levy, Rinath; Cohen, Raphael M.; Zhao, Min

doi:10.1016/j.drudis.2019.05.034

Cited by 7 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 30 At present, intraocular injection of anti-VEGF drugs is widely applied in the treatment of retinal or choroidal neovascular disorders such as DR, retinopathy of prematurity, and AMD. 31 , 32 A large number of experiments have shown that VEGF can be produced by retinal glial (Müller) cells. The inhibition of glial cells can reduce the expression of tumor necrosis factor (TNF) -α, ICAM-1, etc.…”

Section: Main Mechanisms Of Drmentioning

confidence: 99%

Recent Insights into the Role of Gut Microbiota in Diabetic Retinopathy

Jiao¹,

Yu²,

Yao³

et al. 2021

JIR

View full text Add to dashboard Cite

The microbiome has become a hot issue in recent years. The composition, modification, alteration, and disturbance of gut microbiota were found to influence important physiological processes, including energy metabolism and microenvironmental homeostasis, and lead to various diseases, including obesity, type 2 diabetes mellitus and chronic kidney disease. Diabetic retinopathy (DR) is a major microvascular complication of diabetes mellitus and one of the leading causes of blindness and vision impairment. The underlying mechanisms in DR pathogenesis remain limited. Recently, important insights have been made regarding possible connections between gut microbiome dysbiosis and ocular disease including DR, uveitis, glaucoma, and age-related macular degeneration, and the concept of a “microbiota–gut–retina axis” has been put forward. Hence, we reviewed current understanding of the relationship between DR and gut microbiota. We summarized potential pathophysiological mechanisms that contribute to the role of the gut microbiota on DR, including hyperglycemia, anti-diabetes drugs, microbial metabolites, and inflammatory properties. We aimed to find novel effective therapeutic options to prevent the onset and development of DR.

show abstract

Section: Main Mechanisms Of Drmentioning

confidence: 99%

Recent Insights into the Role of Gut Microbiota in Diabetic Retinopathy

Jiao¹,

Yu²,

Yao³

et al. 2021

JIR

View full text Add to dashboard Cite

show abstract

“…During the development of RVO-ME, VEGF plays a key role in vascular permeability, resulting in the appearance of ME [ 11 – 13 ]. Therefore, anti-VEGF drugs have become the first-line treatment for ME, and have been found to be effective in improving vision [ 14 ].…”

Section: Discussionmentioning

confidence: 99%

Combination Therapy Using Anti-Vascular Endothelial Growth Factor (VEGF) Drugs and Steroids for Macular Edema in Retinal Vein Occlusions

et al. 2023

View full text Add to dashboard Cite

Background Retinal vein occlusion-induced macular edema (RVO-ME) is a significant global cause of vision loss, with the effectiveness of combined anti-vascular endothelial growth factor (anti-VEGF) drugs and dexamethasone implantation (DEX I) being a relevant, yet not thoroughly explored, area of interest. The aim of this study was to evaluate the 1-year clinical efficacy of combination therapy using anti-vascular endothelial growth factor (VEGF) drugs and dexamethasone implantation (DEX I) in the treatment of macular edema secondary to retinal vein occlusion (RVO-ME). Material/methods This retrospective study analyzed data from 34 RVO-ME patients treated at the Inner Mongolia Chaoju Eye Hospital between January 2020 and December 2021. All patients underwent initial DEX I treatment, followed by the introduction of anti-VEGF drugs, and were observed for one year. Retinal structural and vascular changes were measured using spectral domain optical coherence tomography (SD-OCT) and OCT angiography (OCTA). The study also evaluated shifts in best corrected visual acuity (BCVA) throughout the observation period. Results Following the combined therapy, patients showed significant improvements in BCVA, intraocular pressure (IOP), central retinal thickness (CRT), and retinal vessel density (VD) (all P <0.05). Upon stratifying the results by RVO type, patients with branch retinal vein occlusion (BRVO)-ME displayed more significant BCVA improvement and CRT reduction at various post-treatment intervals compared to those with central retinal vein occlusion (CRVO)-ME (all P <0.05). Conclusions The combined use of anti-VEGF drugs and DEX I showed promising one-year efficacy in treating RVO-ME, with greater improvements noted in patients with BRVO-ME compared to those with CRVO-ME. Despite the positive results, close monitoring of IOP elevation, a notable side effect, remains crucial.

show abstract

“…VEGF levels are considerably up-regulated in diabetic patients with DME, showing more extensive macular leakage than patients without significant leakage [9]. Anti-VEGF drugs may affect endothelial tight junction proteins and therefore decrease vascular permeability [10].…”

Section: Introductionmentioning

confidence: 99%

Untitled

2021

OCR

View full text Add to dashboard Cite

Objective of the present study was to investigate the effect of chromium polynicotinate supplementation on the visual acuity and macular thickness of the diabetic macular edema in patients with non-proliferative diabetic retinopathy through a prospective, interventional comparative case series study, which was performed in 120 patients. Patients received the supplementation with or without chromium for 4 months and were followed for six months. Best-Corrected Visual Acuity (BCVA), Central Foveal Thickness (CFT), HbA1c, and the frequency of Intravitreal Bevacizumab (IVB) injection were compared. From 120 eligible patients, 90 patients involved in this study and completed the six months' follow-up period. 51 of them were in chromium, and 39 were in the control group. The visual acuity was improved significantly from baseline in all follow-up points in both groups (P<0.05 for all visits compared to baseline), but there was no significant difference between groups. The linear mixed model analysis showed that the mean CFT reduction was not significantly different between both groups in four follow-up visits (P=0.433, P=0.398 and P=0.630, and P=0.151, respectively). HbA1C and the average number of IVB injections were significantly lower in the chromium group, (P=0.032 and P=0.001, respectively). Chromium supplementation did not affect the visual acuity and central foveal thickness of patients with non-proliferative diabetic retinopathy and macular edema but reduced the number of IVB injections and HbA1C levels.

show abstract

Potential antiedematous effects of intravitreous anti-VEGF, unrelated to VEGF neutralization

Cited by 7 publications

References 25 publications

Recent Insights into the Role of Gut Microbiota in Diabetic Retinopathy

Recent Insights into the Role of Gut Microbiota in Diabetic Retinopathy

Combination Therapy Using Anti-Vascular Endothelial Growth Factor (VEGF) Drugs and Steroids for Macular Edema in Retinal Vein Occlusions

Untitled

Contact Info

Product

Resources

About